AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 25445613 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PG)
Number of subjects: 120
Study 23070669 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial Yoga (IY) group
Number of subjects: 0
Study 23070669 — intervention group
Group type: COMPARATOR
Intervention: Enhanced wait-list control (WLC) group
Number of subjects: 0
Study 23070669 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-minute walk distance (6MW)
Number of subjects: 0
Study 23070669 — intervention group
Group type: EXPERIMENTAL
Intervention: Distress related to dyspnea (DD)
Number of subjects: 0
Study 23070669 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional performance (FPI)
Number of subjects: 0
Study 23070669 — intervention group
Group type: EXPERIMENTAL
Intervention: Health-related quality of life (HRQL)
Number of subjects: 0
Study 23070669 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological well-being (anxiety and depression)
Number of subjects: 0
Study 20926021 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg/day
Number of subjects: 23
Study 20926021 — intervention group
Group type: COMPARATOR
Intervention: Rabeprazole 10 mg/day
Number of subjects: 23
Study 17768624 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral approach
Number of subjects: 52
Study 17768624 — intervention group
Group type: COMPARATOR
Intervention: Bilateral approach
Number of subjects: 52
Study 15701497 — intervention group
Group type: EXPERIMENTAL
Intervention: Video-imaging (VI)
Number of subjects: 24
Study 15701497 — intervention group
Group type: COMPARATOR
Intervention: Binocular direct-vision (BDV)
Number of subjects: 24
Study 15701497 — intervention group
Group type: COMPARATOR
Intervention: Monocular direct-vision (MDV)
Number of subjects: 24
Study 12768912 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose of eptifibatide
Number of subjects: 0
Study 12768912 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 10597554 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopamine infusion (3 micrograms.kg‐1.min‐1) (Group A)
Number of subjects: 30
Study 10597554 — intervention group
Group type: COMPARATOR
Intervention: Dextrose infusion (control) (Group B)
Number of subjects: 30
Study 10597554 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 30
Study 8605791 — intervention group
Group type: EXPERIMENTAL
Intervention: 11 ppm inhaled nitric oxide
Number of subjects: 19
Study 8605791 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 ppm inhaled nitric oxide
Number of subjects: 19
Study 8605791 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 ppm inhaled nitric oxide
Number of subjects: 19
Study 8605791 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 ppm inhaled nitric oxide
Number of subjects: 19
Study 29766634 — intervention group
Group type: EXPERIMENTAL
Intervention: Semaglutide 0.5 mg
Number of subjects: 0
Study 29766634 — intervention group
Group type: EXPERIMENTAL
Intervention: Semaglutide 1.0 mg
Number of subjects: 0
Study 29766634 — intervention group
Group type: COMPARATOR
Intervention: Comparators (placebo, sitagliptin, exenatide extended release, insulin glargine)
Number of subjects: 0
Study 26251112 — intervention group
Group type: EXPERIMENTAL
Intervention: Reminiscence therapy (30-35 minutes, once a week for 12 weeks)
Number of subjects: 62
Study 26251112 — intervention group
Group type: COMPARATOR
Intervention: Control group (no reminiscence therapy)
Number of subjects: 62
Study 24025983 — intervention group
Group type: EXPERIMENTAL
Intervention: Mericitabine 500 mg
Number of subjects: 64
Study 24025983 — intervention group
Group type: EXPERIMENTAL
Intervention: Mericitabine 1000 mg
Number of subjects: 64
Study 24025983 — intervention group
Group type: EXPERIMENTAL
Intervention: Mericitabine 2000 mg
Number of subjects: 64
Study 24025983 — intervention group
Group type: COMPARATOR
Intervention: Mericitabine (all doses)
Number of subjects: 64
Study 23134382 — intervention group
Group type: EXPERIMENTAL
Intervention: Pay-for-performance program (Advancing Quality)
Number of subjects: 134435
Study 23134382 — intervention group
Group type: COMPARATOR
Intervention: Control group (other hospitals in England)
Number of subjects: 134435
Study 20216021 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound (US) guidance for femoral nerve blocks
Number of subjects: 11
Study 20216021 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound (US) guidance for sciatic nerve blocks
Number of subjects: 11
Study 20216021 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound (US) guidance
Number of subjects: 11
Study 20216021 — intervention group
Group type: COMPARATOR
Intervention: Alternative techniques (control)
Number of subjects: 11
Study 17935461 — intervention group
Group type: EXPERIMENTAL
Intervention: Domestic violence workshop
Number of subjects: 27
Study 17935461 — intervention group
Group type: COMPARATOR
Intervention: Control workshop
Number of subjects: 27
Study 15679515 — intervention group
Group type: EXPERIMENTAL
Intervention: LEV 1,000 mg
Number of subjects: 883
Study 15679515 — intervention group
Group type: EXPERIMENTAL
Intervention: LEV 333 mg
Number of subjects: 883
Study 15679515 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 883
Study 12215329 — intervention group
Group type: EXPERIMENTAL
Intervention: Transabdominal ultrasound-guided embryo transfer
Number of subjects: 374
Study 12215329 — intervention group
Group type: COMPARATOR
Intervention: Control group (no ultrasound guidance)
Number of subjects: 374
Study 9931651 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard pancreatectomy
Number of subjects: 0
Study 9931651 — intervention group
Group type: EXPERIMENTAL
Intervention: R0 resections
Number of subjects: 0
Study 9931651 — intervention group
Group type: COMPARATOR
Intervention: Adjuvant radiochemotherapy
Number of subjects: 0
Study 7649596 — intervention group
Group type: EXPERIMENTAL
Intervention: Sahaja yoga meditation for 6 months
Number of subjects: 32
Study 7649596 — intervention group
Group type: COMPARATOR
Intervention: Postural exercises mimicking Sahaja yoga for 6 months
Number of subjects: 32
Study 7649596 — intervention group
Group type: COMPARATOR
Intervention: Control group (epileptic control)
Number of subjects: 32
Study 2669119 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole (30 mg)
Number of subjects: 217
Study 2669119 — intervention group
Group type: COMPARATOR
Intervention: Cimetidine (1 g)
Number of subjects: 217
Study 2669119 — intervention group
Group type: EXPERIMENTAL
Intervention: Smokers
Number of subjects: 217
Study 2669119 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-smokers
Number of subjects: 217
Study 2669119 — intervention group
Group type: EXPERIMENTAL
Intervention: Healed prepyloric ulcer
Number of subjects: 217
Study 2669119 — intervention group
Group type: EXPERIMENTAL
Intervention: Healed corpus ulcer
Number of subjects: 217
Study 353659 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose heparin (t.i.d.)
Number of subjects: 40
Study 353659 — intervention group
Group type: COMPARATOR
Intervention: Low dose heparin (t.i.d.) combined with aspirin
Number of subjects: 40
Study 31402492 — intervention group
Group type: EXPERIMENTAL
Intervention: QTcA (patient-specific QT correcting algorithm)
Number of subjects: 1930
Study 31402492 — intervention group
Group type: EXPERIMENTAL
Intervention: QTcA (severely prolonged)
Number of subjects: 1930
Study 31402492 — intervention group
Group type: EXPERIMENTAL
Intervention: QTcA (prolonged)
Number of subjects: 1930
Study 31402492 — intervention group
Group type: EXPERIMENTAL
Intervention: QTcB (prolonged)
Number of subjects: 1930
Study 31402492 — intervention group
Group type: EXPERIMENTAL
Intervention: QTcB
Number of subjects: 1930
Study 31402492 — intervention group
Group type: EXPERIMENTAL
Intervention: QTcA
Number of subjects: 1930
Study 26769823 — intervention group
Group type: EXPERIMENTAL
Intervention: Time and Place Management (TPM) intervention
Number of subjects: 437
Study 26058489 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed electromagnetic fields (PEMFs)
Number of subjects: 50
Study 26058489 — intervention group
Group type: COMPARATOR
Intervention: Sham PEMFs
Number of subjects: 50
Study 23834132 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal azelastine
Number of subjects: 60
Study 23834132 — intervention group
Group type: EXPERIMENTAL
Intervention: Mometasone furoate nasal spray
Number of subjects: 60
Study 23834132 — intervention group
Group type: COMPARATOR
Intervention: Isotonic sea water nasal spray
Number of subjects: 60
Study 21745625 — intervention group
Group type: EXPERIMENTAL
Intervention: Fermented kimchi
Number of subjects: 22
Study 21745625 — intervention group
Group type: COMPARATOR
Intervention: Fresh kimchi
Number of subjects: 22
Study 19880459 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram treatment
Number of subjects: 0
Study 16412160 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRHa/estradiol
Number of subjects: 21
Study 16412160 — intervention group
Group type: COMPARATOR
Intervention: GnRHa/placebo
Number of subjects: 21
Study 16412160 — intervention group
Group type: EXPERIMENTAL
Intervention: Natural menstrual cycles
Number of subjects: 21
Study 12614703 — intervention group
Group type: EXPERIMENTAL
Intervention: Augmented protocol designed to encourage reflection and deliberation
Number of subjects: 0
Study 12614703 — intervention group
Group type: COMPARATOR
Intervention: Standard protocol for eliciting health preferences
Number of subjects: 0
Study 12614703 — intervention group
Group type: EXPERIMENTAL
Intervention: Values-clarification exercise
Number of subjects: 0
Study 11098040 — intervention group
Group type: EXPERIMENTAL
Intervention: Intercourse during the peri-transfer period
Number of subjects: 478
Study 11098040 — intervention group
Group type: COMPARATOR
Intervention: Abstinence from intercourse during the peri-transfer period
Number of subjects: 478
Study 9360699 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mL of fibrin glue added to peritoneal cuff suture
Number of subjects: 19
Study 9360699 — intervention group
Group type: COMPARATOR
Intervention: Control group (no fibrin glue)
Number of subjects: 19
Study 1544289 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg famotidine
Number of subjects: 12
Study 1544289 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 mg quinidine
Number of subjects: 12
Study 1544289 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 4054204 — intervention group
Group type: EXPERIMENTAL
Intervention: Cianergoline (maximum daily dose 12 +/- 2 mg for 4 weeks)
Number of subjects: 20
Study 4054204 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 4054204 — intervention group
Group type: EXPERIMENTAL
Intervention: Cianergoline
Number of subjects: 20
Study 30269640 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated telemedicine intervention (daily phone messages with proactive alerts)
Number of subjects: 168
Study 30269640 — intervention group
Group type: COMPARATOR
Intervention: Control group (daily phone messages without proactive alerts)
Number of subjects: 168
Study 29914666 — intervention group
Group type: EXPERIMENTAL
Intervention: 800 mg/d resveratrol for 8 weeks
Number of subjects: 45
Study 29914666 — intervention group
Group type: COMPARATOR
Intervention: Placebo capsules for 8 weeks
Number of subjects: 45
Study 28031210 — intervention group
Group type: EXPERIMENTAL
Intervention: EXPERT asthma intervention (interactive website)
Number of subjects: 148
Study 28031210 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 148
Study 24968101 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin administration
Number of subjects: 102
Study 24968101 — intervention group
Group type: COMPARATOR
Intervention: Placebo administration
Number of subjects: 102
Study 22994055 — intervention group
Group type: EXPERIMENTAL
Intervention: Compound Xuanju Capsule
Number of subjects: 90
Study 22994055 — intervention group
Group type: COMPARATOR
Intervention: Antibiotics (Control)
Number of subjects: 90
Study 20152605 — intervention group
Group type: EXPERIMENTAL
Intervention: Phacoemulsification
Number of subjects: 200
Study 20152605 — intervention group
Group type: COMPARATOR
Intervention: SICS
Number of subjects: 200
Study 20152605 — intervention group
Group type: EXPERIMENTAL
Intervention: Phacoemulsification (automated counting)
Number of subjects: 200
Study 20152605 — intervention group
Group type: COMPARATOR
Intervention: SICS (automated counting)
Number of subjects: 200
Study 18534951 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemedicine
Number of subjects: 16
Study 18534951 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 16
Study 16293868 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine/carboplatin (GC arm)
Number of subjects: 334
Study 16293868 — intervention group
Group type: COMPARATOR
Intervention: Single-agent gemcitabine (G arm)
Number of subjects: 334
Study 12411222 — intervention group
Group type: EXPERIMENTAL
Intervention: Metergoline
Number of subjects: 0
Study 12411222 — intervention group
Group type: COMPARATOR
Intervention: Diphenhydramine (active placebo)
Number of subjects: 0
Study 12411222 — intervention group
Group type: COMPARATOR
Intervention: Comparison group (unmedicated healthy women)
Number of subjects: 0
Study 9856962 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 9194
Study 9856962 — intervention group
Group type: COMPARATOR
Intervention: Atenolol
Number of subjects: 9194
Study 7664231 — intervention group
Group type: EXPERIMENTAL
Intervention: Liberal use of episiotomy
Number of subjects: 0
Study 7664231 — intervention group
Group type: COMPARATOR
Intervention: Restrictive use of episiotomy
Number of subjects: 0
Study 2228843 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefotaxime
Number of subjects: 78
Study 2228843 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefoxitin
Number of subjects: 78
Study 2228843 — intervention group
Group type: COMPARATOR
Intervention: Clindamycin plus gentamicin
Number of subjects: 78
Study 396056 — intervention group
Group type: EXPERIMENTAL
Intervention: Praziquantel 3 x 20 mg/kg
Number of subjects: 82
Study 396056 — intervention group
Group type: EXPERIMENTAL
Intervention: Praziquantel 1 x 50 mg/kg
Number of subjects: 82
Study 396056 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 82
Study 30948756 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg L-DOPA
Number of subjects: 87
Study 30948756 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg L-DOPA (low-weight participants)
Number of subjects: 87
Study 30948756 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 87
Study 30265586 — intervention group
Group type: EXPERIMENTAL
Intervention: Steroid avoidance (SA)
Number of subjects: 0
Study 30265586 — intervention group
Group type: EXPERIMENTAL
Intervention: Steroid withdrawal (SW)
Number of subjects: 0
Study 30265586 — intervention group
Group type: EXPERIMENTAL
Intervention: Early diagnosis and treatment of glucocorticoid-induced adverse events
Number of subjects: 0
Study 30265586 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk stratification based on pre-transplant risk factors
Number of subjects: 0
Study 28069040 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture, electroacupuncture, and intradermal acupuncture (6 sessions within 8 days starting within 48 hours of craniotomy)
Number of subjects: 40
Study 28069040 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture, electroacupuncture, and intradermal acupuncture
Number of subjects: 40
Study 28069040 — intervention group
Group type: COMPARATOR
Intervention: Conventional management
Number of subjects: 40
Study 26229048 — intervention group
Group type: EXPERIMENTAL
Intervention: Early movement of the ankle between neutral and plantar flexion in a brace for 6 weeks (group 1)
Number of subjects: 50
Study 26229048 — intervention group
Group type: COMPARATOR
Intervention: Achilles tendon immobilization in tension using a below‐knee cast with the ankle in a neutral position for 6 weeks (group 2)
Number of subjects: 50
Study 26229048 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 50
Study 23967631 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupoint sticking + ginger‐separated moxibustion (group A)
Number of subjects: 100
Study 23967631 — intervention group
Group type: COMPARATOR
Intervention: Electroacupuncture + ginger‐separated moxibustion (group E)
Number of subjects: 100
Study 21893447 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast (10 mg/d) for six weeks
Number of subjects: 41
Study 21893447 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide (400 ug b.i.d.) for six weeks
Number of subjects: 41
Study 21893447 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast and Budesonide
Number of subjects: 41
Study 21893447 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast
Number of subjects: 41
Study 21893447 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide and Montelukast
Number of subjects: 41
Study 21893447 — intervention group
Group type: EXPERIMENTAL
Intervention: Induced sputum analysis
Number of subjects: 41
Study 18199572 — intervention group
Group type: EXPERIMENTAL
Intervention: Pacing with preventive pacing algorithms (PPA)
Number of subjects: 199
Study 18199572 — intervention group
Group type: EXPERIMENTAL
Intervention: Pacing with preventive pacing algorithms (PPA) + anti-tachycardia pacing (ATP)
Number of subjects: 199
Study 18199572 — intervention group
Group type: COMPARATOR
Intervention: Pacing with preventive pacing algorithms (PPA) + ATP
Number of subjects: 199
Study 17018345 — intervention group
Group type: EXPERIMENTAL
Intervention: PMOP 90 bpm for 10 minutes
Number of subjects: 50
Study 17018345 — intervention group
Group type: EXPERIMENTAL
Intervention: PMOP 120 bpm for 10 minutes
Number of subjects: 50
Study 17018345 — intervention group
Group type: EXPERIMENTAL
Intervention: PMOP 90 bpm for 30 minutes (nonrandomized)
Number of subjects: 50
Study 17018345 — intervention group
Group type: COMPARATOR
Intervention: PMOP settings
Number of subjects: 50
Study 12623744 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E (400 mg) and selenium (225 microg) supplementation for 3 months
Number of subjects: 54
Study 12623744 — intervention group
Group type: COMPARATOR
Intervention: Vitamin B (4.5 g/day) for 3 months
Number of subjects: 54
Study 10846776 — intervention group
Group type: EXPERIMENTAL
Intervention: Middle cerebral artery (MCA) Doppler
Number of subjects: 47
Study 10846776 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated HC/AC ratio
Number of subjects: 47
Study 10846776 — intervention group
Group type: COMPARATOR
Intervention: Normal umbilical artery Doppler waveforms
Number of subjects: 47
Study 9126892 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous therapy with continuous IGF‐I (0.01 mg/kg/hour)
Number of subjects: 33
Study 9126892 — intervention group
Group type: COMPARATOR
Intervention: Standard neurosurgical intensive care plus aggressive nutritional support (Control)
Number of subjects: 33
Study 8437596 — intervention group
Group type: EXPERIMENTAL
Intervention: Interleukin-1 alpha (0.3 microgram per kilogram after carboplatin)
Number of subjects: 43
Study 8437596 — intervention group
Group type: EXPERIMENTAL
Intervention: Interleukin-1 alpha (0.1 or 0.3 microgram per kilogram after carboplatin)
Number of subjects: 43
Study 8437596 — intervention group
Group type: COMPARATOR
Intervention: High-dose carboplatin alone (800 mg per square meter)
Number of subjects: 43
Study 8437596 — intervention group
Group type: EXPERIMENTAL
Intervention: Interleukin-1 alpha (before carboplatin)
Number of subjects: 43
Study 3834841 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloroquine chemoprophylaxis
Number of subjects: 198
Study 3834841 — intervention group
Group type: COMPARATOR
Intervention: Control (no chloroquine chemoprophylaxis)
Number of subjects: 198
Study 31971304 — intervention group
Group type: EXPERIMENTAL
Intervention: Dementia Care Competence Scale training
Number of subjects: 308
Study 31971304 — intervention group
Group type: EXPERIMENTAL
Intervention: Dementia care training
Number of subjects: 308
Study 31971304 — intervention group
Group type: EXPERIMENTAL
Intervention: Demographic factors (age, seniority, experience with dementia)
Number of subjects: 308
Study 31891347 — intervention group
Group type: EXPERIMENTAL
Intervention: Disability simulation activity
Number of subjects: 88
Study 31891347 — intervention group
Group type: COMPARATOR
Intervention: Accessibility audit activity
Number of subjects: 88
Study 29316336 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive, web‐based parenting tutorial
Number of subjects: 104
Study 29316336 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 104
Study 26919410 — intervention group
Group type: EXPERIMENTAL
Intervention: Secukinumab 150 mg s.c. at baseline, week 1, 2, 3, and 4, then every 4 weeks (with up-titration to 300 mg for 2 non-responders)
Number of subjects: 12
Study 26366971 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine intake
Number of subjects: 1549
Study 26366971 — intervention group
Group type: COMPARATOR
Intervention: Creatine intake
Number of subjects: 1549
Study 22694666 — intervention group
Group type: EXPERIMENTAL
Intervention: Developing Nurses' Thinking (DNT) model during 2 weeks of clinical postconferences
Number of subjects: 83
Study 20231321 — intervention group
Group type: EXPERIMENTAL
Intervention: No-dose-reduction group (initial optimal therapeutic dose continued throughout the study)
Number of subjects: 404
Study 20231321 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-week group (initial optimal therapeutic dose continued for 4 weeks, followed by a 50% dose reduction)
Number of subjects: 404
Study 20231321 — intervention group
Group type: EXPERIMENTAL
Intervention: 26-week group (initial optimal therapeutic dose continued for 26 weeks, followed by a 50% dose reduction)
Number of subjects: 404
Study 18341673 — intervention group
Group type: EXPERIMENTAL
Intervention: Brivaracetam 200 mg/day
Number of subjects: 36
Study 18341673 — intervention group
Group type: EXPERIMENTAL
Intervention: Brivaracetam 400 mg/day
Number of subjects: 36
Study 18341673 — intervention group
Group type: EXPERIMENTAL
Intervention: Brivaracetam 800 mg/day
Number of subjects: 36
Study 18341673 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 16122468 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled additional pulmonary blood flow (group A, n = 29)
Number of subjects: 38
Study 16122468 — intervention group
Group type: COMPARATOR
Intervention: Bidirectional Glenn procedure only (group B, n = 9)
Number of subjects: 38
Study 16122468 — intervention group
Group type: COMPARATOR
Intervention: Bidirectional Glenn procedure only (group B)
Number of subjects: 38
Study 16122468 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled additional pulmonary blood flow (group A)
Number of subjects: 38